FarmaKology-Gaza's elderly face war, displacement and medicine shortages

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to "abdul@farmakology.com", and happy to have you featured on our newsletter+21K Subs.

Today's Company

Carina Biotech

Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing.

News

Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Ona Therapeutics , a Spanish biotech company specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer.Under the terms of the agreement, Biocytogen will grant Ona access to evaluate Biocytogen’s proprietary RenMice®-derived fully human antibodies against a specific tumor target, with an option to exclusively license selected antibodies for antibody-drug conjugate (ADC) development, manufacturing and commercialization in mutually agreed indications and territories.

Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications

Anagenex and Nimbus Therapeutics today announced they have initiated a research collaboration. Anagenex, a pioneering drug discovery company pairing large-scale data generation with proprietary artificial intelligence, will work closely with Nimbus to discover small molecule drugs for multiple challenging targets.Through this multi-target collaboration, the companies will apply Anagenex’s AI driven parallel biochemistry platform to generate billions of experimentally measured datapoints for each of Nimbus’ nominated targets. Anagenex will then use the resulting data to train proprietary AI models that will generatively design 100 million new target-specific molecules to experimentally probe structure activity relationships at an unprecedented scale and speed ultimately identifying highly selective and potent drug candidates.

Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program of its discovery and development collaboration with GenFleet Therapeutics . “We are pleased to announce this oral KRAS G12D inhibitor with a potential best-in-class profile as the lead program from our collaboration with GenFleet supporting our mission to bring needed therapies to patients with RAS pathway-driven cancers,” said Dan Paterson, President and Chief Executive Officer of Verastem Oncology. “Although there has been significant progress in therapeutics targeting KRAS mutations, there are currently no available therapies approved by the U.S. Food and Drug Administration targeting KRAS G12D, the most prevalent KRAS mutation across human cancers.

BioMap and GeneQuantum establish a strategic collaboration to jointly develop a series of next-generation ADC therapeutics

BioMap, a global leader in life science AI Foundation protein-centric Large Language Models, and GeneQuantum Healthcare , a global leader in ADC new drug development focused on innovative bioconjugation technologies, announced that they have entered into a strategic collaboration agreement to co-develop FIC/BIC ADC therapeutics for multiple targets. The partnership will combine GQ’s proprietary enzymatic site-specific conjugation technology platforms (iLDC® and iGDC®), linker-payload platform, with BioMap’s life science AI Foundation Large Language Model xTrimo and AI protein generation platform AIGP, to create novel ADCs addressing high unmet medical needs.

Research & Study

New AI Framework to Identify New Indications for Existing Drugs

mRNA-4157 Plus Pembrolizumab Continues to Improve RFS in High-Risk Melanoma

New discovery could expand the possibilities for medical use of Botox

Chia seeds have great potential to improve human health

Podcast

Job Opportunities

Medical Representative

Pharmacy Technician

clinical pharmacist

Pharmacist

Upcoming Webinar & Event

PepTalk - The Protein Science and Production Week

How to Get the Most Out of Nitinol for Your Medical Device Application

Video